View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 21, 2020updated 12 Jul 2022 11:57am

VBL Therapeutics initiates VB-111’s trial in colorectal cancer

VBL Therapeutics has initiated a Phase II clinical trial of a VB-111 and Opdivo (nivolumab) combination to treat patients with metastatic colorectal cancer (CRC).

VBL Therapeutics has initiated a Phase II clinical trial of a VB-111 and Opdivo (nivolumab) combination to treat patients with metastatic colorectal cancer (CRC).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

VB-111, also called ofranergene obadenovec, is a gene therapy being developed to treat various solid tumours, while nivolumab is a human monoclonal antibody targeting PD-1.

The open-label, single-arm Phase II trial will assess the safety and tolerability of the combination in patients with refractory, metastatic CRC. It aims to determine if the anti-tumour immunity triggered by VB-111 can be boosted by PD-1 inhibition.

Treatment with VB-111 is expected to stimulate immune cells to enter the tumour, turning the colorectal tumour from immunologically ‘cold’ to ‘hot.’ The further addition of nivolumab may boost the anti-tumour immune response.

The trial will also track efficacy endpoints including best overall response, along with immunological and histologic analysis using tumour biopsies.

This study will be funded by the National Cancer Institute (NCI), which signed a cooperative research and development agreement with VBL.

VBL Therapeutics CEO Dror Harats said: “This Phase II study is part of our strategy to broaden the potential indications for VB-111 and to explore its activity as part of combination therapies.

“We look forward to collaborating with NCI on this clinical trial, as we continue to generate data which adds to our understanding of VB-111’s mechanism of action and therapeutic potential.

“We were particularly encouraged by results in ovarian cancer demonstrating the recruitment of infiltrating T-cells into a tumour following treatment with VB-111, turning the tumour ‘hot’.”

Last month, the company published clinical data from the Phase II and Phase III studies of VB-111 in recurrent glioblastoma (rGBM). Results were published in the peer-reviewed medical journal Neuro-Oncology.

VB-111 is also currently being studied in a Phase III study in ovarian cancer.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena